Reports

Generics makers challenging more patents

Home/Reports | Posted 05/12/2014

In recent years generics makers are becoming bolder and challenging more patents on originator drugs. In fact, litigation regarding patents on pharmaceuticals is on the rise, particularly when it comes to newer drugs.

Generics and biosimilars contribute to European drug savings

Home/Reports | Posted 17/10/2014

As governments around the world try to rein in healthcare expenses, generics and biosimilars can play a major role in reducing this budgetary burden [1, 2].

Growth in Netherlands pharma market held back by generics policies

Home/Reports | Posted 21/11/2014

The pharmaceutical market in The Netherlands will rise slowly from approximately US$6.7 billion in 2014 to US$7.2 billion by 2020. Growth is being restricted by the government’s focus on generics as a cost-containment tool, according to research and consulting firm GlobalData.

Biosimilars use in Europe varies widely

Home/Reports | Posted 14/11/2014

Use of biosimilars in Europe varies widely between countries and therapy areas, according to a report published by IMS Health in October 2014.

Development of biosimilars for rheumatoid arthritis

Home/Reports | Posted 07/11/2014

Biosimilars development is a hive of activity, with development of biosimilars for the treatment of rheumatoid arthritis being one of the busiest areas in the biosimilars field, see Table 1 [1].

Patients satisfied with generics

Home/Reports | Posted 31/10/2014

A report by health information resource, Iodine, has found that patients have a similar level of satisfaction with generics compared to brand-name drugs.

Generics save US 1.5 trillion over last 10 years

Home/Reports | Posted 24/10/2014

Generics have saved consumers and the US healthcare system US$239 billion in 2013 and have saved the US nearly US$1.5 trillion between 2004 and 2013, according to a report by the Generic Pharmaceutical Association (GPhA) [1].

Elderly patients in US lack knowledge on biosimilars

Home/Reports | Posted 10/10/2014

A survey conducted by patient advocacy group RetireSafe finds that seniors are largely unaware of biosimilars and that they overwhelmingly support strong patient safeguards and notification of patients and physicians when biosimilar substitution takes place.

Global and national biosimilars players increasing

Home/Reports | Posted 03/10/2014

The number of players in the biosimilars field is increasing with both originator and generics manufacturers devoting resources to biosimilars. This applies to global companies as well as to national players [1].

Biosimilars in emerging markets

Home/Reports | Posted 19/09/2014

Less strict or ‘relaxed’ regulatory requirements for biosimilars in some emerging markets are driving the proliferation of non-originator biologicals [1].

Biosimilar events from 2012 to 2014

Home/Reports | Posted 14/08/2014

The last few years have seen biosimilars the hot topic on the agenda of most countries. This is evidenced by the increasing number of biosimilars manufacturers as well as approvals for biosimilars around the world [1].

Use of biosimilars in Europe differs across countries

Home/Reports | Posted 08/08/2014

In Europe, the use of biosimilars exhibits different rates in different countries. This can lead to inequalities in access to biologicals, for instance, for the treatment of autoimmune diseases such as arthritis [1].

Healthcare providers concerned about FDA’s generics labelling rules

Home/Reports | Posted 01/08/2014

A survey by the Generic Pharmaceutical Association (GPhA) and the National Coalition on Healthcare (NCH) has revealed that healthcare providers have serious concerns about the US Food and Drug Administration’s (FDA) proposed new rules for generics labels.

Biologicals dominate Europe’s best sellers

Home/Reports | Posted 27/06/2014

The landscape of blockbuster medicines in Europe has been changing over the last years from small molecule drugs to biologicals.

Factors supporting a sustainable European biosimilars market

Home/Reports | Posted 20/06/2014

Factors that will support a sustainable biosimilars market in Europe include education, encouraging competition, publication of real-world evidence and transparent decision-making processes, according to a report published by the European Generic medicines Association (EGA).

US will continue to buy Indian generics despite quality concerns

Home/Reports | Posted 06/06/2014

According to a recent report by India’s most respected rating agency the high number of import alerts issued by the US Food and Drug Administration (FDA) in 2013 will have no impact on the existing US exports revenue of Indian pharmaceutical manufacturers.

The global biologicals market

Home/Reports | Posted 13/06/2014

Global spending on medicines is expected to reach the US$1 trillion threshold in 2014 and rise to US$1.2 trillion by 2017.

Patients’ perception of generics in the Philippines

Home/Reports | Posted 02/06/2014

A survey of patients in the Philippines showed that less than half were offered a generic drug alternative and even fewer asked for a generic drug alternative. The survey also revealed that patients preferred brand-name medicines over generics [1].

Physicians’ views on generics in the Philippines

Home/Reports | Posted 23/05/2014

A survey of physicians in the Philippines has revealed that five out of six drugs are prescribed using generic names, with physicians in the public sector prescribing generics significantly more often than those in the private sector [1].

Cost-cutting in Europe may affect generics sustainability

Home/Reports | Posted 18/04/2014

According to a presentation by Mr Victor Lino Mendonça, the continued focus on short-term cost containment measures may lead to an unsustainable market environment for generics and biosimilars in the European Union (EU). Mr Mendonça gave his presentation at the International Generic Pharmaceutical Alliance (IGPA)’s 16th Annual Conference, which was held in Brussels, Belgium, 9–11 December 2013 [1].

Generics and biosimilars Initiative

News

Research

General